




Ipca Laboratories Ltd.

Corporate Presentation

June 2023




Incorporation	:	1949
Present Management	:	Since 1975
Total income F. Y. 2022-23	:	Rs. 5925.81 Crs / US\$ 739 Mn (Standalone) Rs. 6369.94 Crs / US\$ 794 Mn (Consolidated)
Exports F. Y. 2022-23	:	Rs. 2643.42 Crs / US\$ 330 Mn
Business Model	:	Integrated pharmaceutical company producing Branded and Generics Formulations, APIs and Intermediates

	2018-19	2019-20	2020-21	2021-22	2022-23
Domestic Income (Rs. Crs)	1,956.90	2,288.37	2,484.21	2,983.09	3,282.39
Domestic Income (US \$ Mn)	276.24	323.03	333.94	400.58	409.17
Export Income (Rs. Crs)	1,730.84	2,143.75	2,717.19	2,508.13	2,643.42
Export Income (US \$ Mn)	244.33	302.62	365.26	336.80	329.52
Total Income (Rs. Crs)	3,687.74	4,432.12	5,201.40	5,491.22	5,925.81
Total Income (US \$ Mn)	520.57	625.65	699.20	737.38	738.69
Net Profit After Tax (Rs. Crs)	454.91	652.46	1,140.77	860.37	505.70
Net Profit After Tax (US \$ Mn)	64.22	92.10	153.35	115.53	63.04

	2018-19	2019-20	2020-21	2021-22	2022-23
Domestic Income (Rs. Crs)	1,956.90	2,327.88	2,519.77	3,077.75	3,391.07
Domestic Income (US \$ Mn)	276.24	328.61	338.72	413.29	422.72
Export Income (Rs. Crs)	1,873.96	2,387.83	2,963.06	2,818.61	2,978.87
Export Income (US \$ Mn)	264.53	337.07	398.31	378.49	371.34
Total Income (Rs. Crs)	3,830.86	4,715.71	5,482.83	5,896.36	6,369.94
Total Income (US \$ Mn)	540.77	665.68	737.03	791.78	794.06
Net Profit After Tax (Rs. Crs)	442.22	603.56	1,140.01	884.08	471.32
Net Profit After Tax (US \$ Mn)	62.43	85.20	153.25	118.72	58.75

Manufacturing Facilities

Formulations




Location	Dosage Form	Approvals / Inspections
Athal (Dadra & Nagar Haveli)	Tablets & Capsules	UK-MHRA, TGA-Australia, WHO-Geneva, EU Certification by German Authority, Health Canada, GCC, MOH-Columbia, FDA Ghana, MOH Oman, NDA - Uganda, NHRA – Bahrain, Medicine and Drug Control - Ukraine, CDSCO – India, MOH Kenya, TMDA Tanzania, MOH Russia, Republic of Yemen
Ratlam (Madhya Pradesh)	Tablets, Liquids, Dry Syrup, Injectables & Ointments	MCC-South Africa, INVIMA Colombia, WHO-Geneva, State Administration of Ukraine, MOH Belarus, NAFDAC-Nigeria, DIGEMID Peru, FDA Ghana, MOH Tanzania, MOH Russia, MCA-Zimbabwe, NDA – Uganda, MOH – Yemen, CDSCO – India.
Kandla (Gujarat)	Betalactum – Tablets, Capsules & Dry Syrups	UK-MHRA, MCC-South Africa, TGA- Australia, National Drug Authority (NDA)- Uganda, Agency for Medicinal Products and Medical Devices (HALMED) – Croatia, TFDA - Tanzania, Zimbabwe -MCAZ, Ivory Coast- ICHA, NAFDAC CGMP - Nigeria, GCC, FDA Ghana, Philippines, Supreme Board for Medicine and Medical Appliances / MoH – Yemen, INVIMA, Columbia, Ministry of Industry and Trade of Russian Federation, Russia

Location	Dosage Form	Approvals / Inspections
Silvassa (Dadra & Nagar Haveli)	Tablets & Capsules	WHO-cGMP, TGA-Australia, Health-Canada, Local FDA
Dehradun, (Uttarakhand)	Tablets & Cephalosporin Injectables	Unit - I : GMP under Schedule M (CDSCO+FDA), GMP & GLP (FDA Uttarakhand) Unit - II: GMP under Schedule M (CDSCO+FDA), GMP & GLP (FDA Uttarakhand,) Ivory Coast Republic of Ivory Coast (Ministry of Medical Services)
Indore (SEZ), (Madhya Pradesh)	Tablets & Capsules	UK-MHRA, Health Canada, MCC-South Africa, TGA – Australia, WHO GMP, WHO Geneva
Sikkim	Tablets & Capsules	ISO 9001, ISO 14001, ISO OHSAS 1800, WHO GMP
Tarapur ,Palghar (Maharashtra)	Tablets	WHO-GMP NDA (Uganda), Pharmacy & Poisons Board- MOH (Nairobi, Kenya) ⁷


Manufacturing Facilities





Active Pharmaceutical Ingredients (APIs)



Location	Approvals / Inspections
Ratlam (Madhya Pradesh)	TGA-Australia, EDQM, PMDA-Japan, WHO-Geneva, Health Canada, EU-GMP (LaGesso, Berlin), MOH Russia, MFDS (Korea), CDSCO- India, Cofepris (Mexico), EU WC, ANVISA (Brazil)
Indore (Madhya Pradesh)	WHO-Geneva, CDSCO- India, EU WC
Dewas (Madhya Pradesh)	CDSCO - India
Ankleshwar (Gujarat)	PMDA –Japan, CDSCO- India, Cofepris (Mexico), EU WC
Nandesari (Gujarat)	CDSCO- India, EU WC
Aurangabad (Maharashtra)	USFDA, MOH Russia, MFDS, CDSCO- India, EU WC, TGA
Mahad (Maharashtra)	State FDA
Ranu (Taluka Padra) (Gujarat)	CDSCO- India, Cofepris (Mexico), EU WC
Tarapur (Ramdev Chemical Pvt. Ltd., Boisar (Maharashtra)	USFDA, CDSCO- India, EU WC


Revenue Break-up





Rs. Crs	2022--23			2021-22			Growth
	Domestic	Exports	Total	Domestic	Exports	Total	
Branded Formulations	2760.71	504.79	3265.50	2508.27	415.99	2924.26	11.7%
Generic/ Institution/ Tender Formulations	-	1134.40	1134.40	-	1070.75	1070.75	5.9%
Total Formulations	2760.71	1639.19	4399.90	2508.27	1486.74	3995.01	10.1%
API / Intermediates	373.05	1004.23	1377.28	358.7	1021.39	1380.09	-0.2%
Others	148.63	-	148.63	116.12	-	116.12	
Total Income	3282.39	2643.42	5925.81	2983.09	2508.13	5491.22	7.9%
Growth	10.0%	5.4%	7.9%				

Financials



F.Y. 2022 - 23			F.Y. 2021 - 22		
	Rs. Crs	US\$ Mn	Rs. Crs	US\$ Mn	% Growth
Total Income	5925.81	739	5491.22	737	8%
EBIDT	1054.05	131	1259.52	169	-16%
EBIDT %	17.79%		22.94%		
PBT #	750.49	94	1074.11	144	-30%
PBT %	12.66%		19.56%		
PAT #	505.70	63	860.37	116	-41%
PAT %	8.53%		15.67%		

After forex loss of Rs. 31.01 Crs as against forex gain of Rs. 31.48 Crs for previous year.

Profitability	FY 2022-23	FY 2021-22
PBIDT	17.79%	22.94%
PBT	12.66%	19.56%
PAT	8.53%	15.67%

Business Characteristics	FY 2022-23	FY 2021-22
Return on Capital Employed % (PBIT / Capital Employed)	11.59%	17.85%
Return on Net Worth % (PAT / Net Worth)	8.60%	15.71%
Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets)	2.28	2.24
Capital Employed Turnover Ratio (Total Income / Capital Employed)	0.86	0.91
Asset Coverage Ratio (to term loan) (Net Fixed Assets / Total Long Term Borrowings)	3.27	5.79
Long Term Debt Equity Ratio (Total Long Term Borrowings / Net Worth)	0.14	0.08
Debtors Turnover Ratio (Days) (Trade Receivables / Turnover) x 365	58.50	55.97
Creditors Turnover Ratio (Days) (Trade Payables / Purchases) x 365	104.02	108.12
Inventory Turnover Ratio (Days) (Inventory / Turnover) x 365	104.89	120.84

Growth	FY 2022-23	FY 2021-22
Net Total Income	7.9%	4.9%
Domestic Sales	9.3%	19.7%
Export Sales	5.4%	-7.9%
PBIDT	-16.3%	-17.4%
PBT	-30.1%	-21.1%
Net Profit	-41.2%	-23.7%

Q1 FY24			Q1 FY23		
	Rs. Crs	US\$ Mn	Rs. Crs	US\$ Mn	% Growth
Total Income	1531.87	186	1496.24	193	2%
EBIDT	284.08	35	269.27	35	6%
EBIDT %	19.08%		18.21%		
PBT #	249.58	30	211.39	27	18%
PBT %	16.76%		14.30%		
PAT #	166.58	20	140.07	18	19%
PAT %	11.19%		9.47%		

After forex gain of Rs. 13.45 Crs as against forex loss of Rs. 14.25 Crs for previous quarter.

F.Y. 2022 - 23			F.Y. 2021 - 22		
	Rs. Crs	US\$ Mn	Rs. Crs	US\$ Mn	% Growth
Total Income	6369.94	794	5896.36	792	8%
EBIDT	1083.77	135	1345.04	181	-19%
EBIDT %	17.01%		22.81%		
PBT #	745.29	93	1135.72	153	-34%
PBT %	11.70%		19.26%		
PAT #	471.32	59	884.08	119	-47%
PAT %	7.40%		14.99%		

After forex loss of Rs. 31.38 Crs as against forex gain of Rs. 30.79 Crs for previous year.

Business Characteristics	FY 2022-23	FY 2021-22
Return on Capital Employed % (PBIT / Capital Employed)	15.21%	18.65%
Return on Net Worth % (PAT / Net Worth)	10.58%	15.95%
Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets)	2.92	2.18
Capital Employed Turnover Ratio (Total Income / Capital Employed)	1.23	0.96
Asset Coverage Ratio (to term loan) (Net Fixed Assets / Total Long Term Borrowings)	3.63	6.40
Long Term Debt Equity Ratio (Total Long Term Borrowings / Net Worth)	0.13	0.08
Debtors Turnover Ratio (Days) (Trade Receivables / Turnover) x 365	43.82	57.65
Creditors Turnover Ratio (Days) (Trade Payables / Purchases) x 365	81.74	109.15
Inventory Turnover Ratio (Days) (Inventory / Turnover) x 365	77.24	117.60

Growth	FY 2022-23	FY 2021-22
Net Total Income	8.0%	7.5%
Domestic Sales	9.5%	22.7%
Export Sales	5.7%	-4.9%
PBIDT	-19.4%	-14.1%
PBT	-34.4%	-18.2%
Net Profit	-46.7%	-22.4%


Q1 FY24			Q1 FY23		
	Rs. Crs	US\$ Mn	Rs. Crs	US\$ Mn	% Growth
Total Income	1632.43	199	1607.85	208	2%
EBIDT	294.13	36	283.46	37	4%
EBIDT %	18.53%		17.88%		
PBT #	251.82	31	222.69	29	13%
PBT %	15.86%		14.04%		
PAT #	162.82	20	143.06	18	14%
PAT %	10.26%		9.02%		

After forex gain of Rs. 13.49 Crs as against forex loss of Rs. 14.23 Crs for previous quarter.

Therapeutic Segment	Domestic		Exports	
	2022-23	2021 - 22	2022-23	2021 - 22
Non Steroidal Anti-Inflammatory Drugs (NSAID)	52%	49%	28%	24%
Cardiovasculars & Anti-Diabetics	16%	17%	24%	25%
Anti-Bacterials	6%	7%	6%	6%
Anti-Malarials	3%	5%	22%	24%
Gastro-Intestinal (GI) Products	2%	3%	5%	6%
Neuro Psychiatry	3%	3%	5%	7%
Cough Preparations	5%	5%	1%	2%
Dermatology	6%	5%	-	-
Urology	4%	3%	-	-
Neutraceuticals	1%	1%	-	-
Others	2%	2%	9%	6%
Total	100%	100%	100%	100%


Branded Formulations

Domestic



- All India Rank IQVIA : 17th (MAT June'23).
- 24 Depots & 1 C&F agents.
- 21 Therapy Focused Marketing Divisions.
- Field Strength (PSR/ BA)– 6180
- Over 4000 Wholesalers.
- 5 brands among top 300 brands (Zerodol-SP, Zerodol-P, HCQS, Folitrax & Zerodol TH).
- Market leaders in Rheumatoid Arthritis & Anti-malarials .


Sales



Future Growth Drivers

- Clinical research as a tool to launch innovative combination formulations / NDDS.
- Strong Brand building with focused promotion.
- In licensing/ out licensing to build business in the promoted therapy.
- Portfolio optimization, strategies to identify need gaps to build, enter, maintain and exit approach.


International Business



- Products of the company are now exported to over 100 countries across the globe.
- Recognized Star Trading House.
- 41% sales from exports.
- Field-force to promote brands in more than 35 countries of CIS, South East Asia, Middle East, Latin America and Africa.

- Marketing offices in Russia, Ukraine, Kazakhstan, Belarus , Vietnam, Philippines, Sri Lanka, Myanmar Kenya, Colombia, and Nigeria & Mexico (subsidiary company).
- Formulation dossiers for branded formulations registered in 58 countries.


Sales




Continent-wise Exports 2022 -23 (Rs. Crs)

Continent	Formulations	Bulk Drugs / Intermediates	Total	% Contribution
Europe	486.11	273.53	759.64	29%
Africa	416.76	55.05	471.81	18%
Americas	163.17	297.79	460.96	17%
Asia	110.82	341.52	452.34	17%
CIS	188.44	32.53	220.97	8%
Australasia	273.89	3.81	277.70	11%
Total	1639.19	1004.23	2643.42	100%


International Formulations




Sales



International Branded Formulations



Sales




Future Growth Drivers


- Thrust on brand building in Pain, CVS, CNS, Anti-infective and Anti-malarial segments.
- Geographical expansion in covered countries through additional field force.
- Expansion in business lines - Institutions and Distributors.
- Introduction of new products - Existing developed formulations are identified for registration and launch across all continents.

International

Generics/ Institution/ Tender



Sales



Country	Products Registered	Products Under Registration
United Kingdom / Europe	92	6
Australia / New Zealand	73	3
South Africa	52	11
United States / Canada	35	26


Future Growth Drivers

- Dossiers developed by company approved in UK are being taken for registration in other EU countries.
- Formulations registered to be backed by own API.
- Sale of generic dossiers with or without supply agreements.
- Contract manufacturing arrangements.


Future Growth Drivers – North America

- Strategic tie up with 3 marketing partners for sale/distribution of Generic formulations.
- 44 ANDAs filed of which 18 ANDAs are approved.
- Exploring contract development and manufacturing opportunities.

International APIs



Sales



Sr. No.	Name of the API	US-FDA	Canada-HPFB	WHO	Japan - PMDA	Australia	EDQM
1	Alendronate Sodium	✓			✓		✓
2	Allopurinol	✓	✓			CEP	✓
3	Amlodipine Besylate	✓					✓
4	Amodiaquine Hcl			✓			
5	Artemether			✓		✓	
6	Artesunate			✓			
7	Artesunate Sterile			✓			
8	Atenolol	✓	✓		✓	CEP	✓
9	Atovaquone						✓
10	Bendroflumethiazide						✓
11	Benzarone				✓		
12	Benzbromarone				✓		
13	Bisoprolol Fumarate	✓	✓				✓
14	Carvedilol	✓	✓				✓
15	Cetirizine Hydrochloride (CZ Process)	✓					

Sr. No.	Name of the API	US-FDA	Canada-HPFB	WHO	Japan - PMDA	Australia	EDQM
16	Cetirizine Hydrochloride (CZ5/CZ6 Process)	✓				CEP	✓
17	Chloroquine Phosphate	✓					✓
18	Chlorthalidone (CT3/CT7 Process)	✓	✓				✓
19	Chlorthalidone (CT6 Process)	✓					✓
20	Citalopram HBR						✓
21	Dihydroartemisinin			✓			
22	Etodolac (ED6 Process)	✓					
23	Etodolac (ED7 Process)	✓					✓
24	Famotidine				✓		✓
25	Famotidine (FM3 Process)						✓
26	Fenofibrate						✓
27	Fluconazole						✓
28	Flumequine						✓
29	Furosemide	✓	✓		✓	CEP	✓
30	Furosemide (Veterinary)		✓				

Sr. No.	Name of the API	US - FDA	Canada- HPFB	WHO	Japan - PMDA	Australia	EDQM
31	Glimepiride	✓			✓		✓
32	Hydrochlorothiazide (Process I)	✓	✓		✓	CEP	✓
33	Hydrochlorothiazide (Process II)	✓					✓
34	Hydrochlorothiazide (Process III)						✓
35	Hydroxychloroquine Sulphate	✓	✓			✓	✓
36	Hydroxyzine Di Hcl	✓					✓
37	Indapamide	✓	✓				✓
38	Lamotrigine						✓
39	Losartan Potassium (LB3 Process)	✓					
40	Losartan Potassium (LB4 Process)						✓
41	Losartan Potassium (LB7 Process)		✓				✓
42	Lumefantrine			✓			
43	Mesalamine (MZ4 Process)	✓					✓
44	Mesalazine						
45	Mesalazine (MZ4B Process)						✓

Sr. No.	Name of the API	US-FDA	Canada-HPFB	WHO	Japan - PMDA	Australia	EDQM
46	Metformin HCL (ML Process)	✓					
47	Metformin HCL (ML2 Process)	✓	✓			CEP	✓
48	Methylphenidate HCL		✓			CEP	✓
49	Metoclopramide Base				✓		
50	Metoclopramide HCl					CEP	✓
51	Metoclopramide HCl (M Process)	✓	✓				
52	Metoprolol Succinate	✓				CEP	✓
53	Metoprolol Tartrate	✓	✓		✓	CEP	✓
54	Metoprolol Tartrate (O3/O5 Process)	✓					
55	Midodrine Hydrochloride	✓					
56	Nabumetone	✓					✓
57	Nifedipine				✓		✓
58	Olanzapine	✓					
59	Ondansetron Base	✓	✓			✓	
60	Ondansetron Hydrochloride	✓	✓			CEP	✓

Sr. No.	Name of the API	US - FDA	Canada- HPFB	WHO	Japan - PMDA	Australia	EDQM
61	Paroxetine Hcl					CEP	✓
62	Piperaquine Phosphate			✓			
63	Primaquine Phosphate	✓				✓	
64	Probenecid	✓					
65	Proguanil Hydrochloride	✓					✓
66	Promethazine Hydrochloride	✓					
67	Propranolol HCl	✓	✓		✓	CEP	✓
68	Pyrantel embonate		✓				✓
69	Pyrantel Pamoate	✓					
70	Pyrimethamine	✓					✓
71	Quetiapine Fumarate	✓	✓			CEP	✓
72	Ractopamine Hcl	✓	✓				
73	Risedronate Sodium Hemi-Pentahydrate	✓					
74	Risperidone	✓					
75	Telmisartan						✓

Sr. No.	Name of the API	US- FDA	Canada- HPFB	WHO	Japan - PMDA	Australia	EDQM
76	Telmisartan (WT3A Process)	✓					
77	Torsemide	✓					✓
78	Tramadol Hydrochloride	✓					
79	Tramadol Hydrochloride (YT2 Process)						✓
80	Tramadol Hydrochloride (YT3 Process)		✓				✓
81	Triamterene	✓					✓
82	Trimethoprim				✓	CEP	✓
83	Trimethoprim (T Process)	✓					
84	Trimethoprim (T4 Process)	✓					
85	Valsartan (VA2 Process)		✓				
86	Valsartan (VA6 Process)	✓					✓
87	Venlafexine Hydrochloride	✓					✓
88	Warfarin Sodium					CEP	✓
89	Warfarin Sodium Clathrate	✓					✓
90	Zaltoprofen				✓		

Sr. No.	Name of the API	US-FDA	Canada-HPFB	WHO	Japan - PMDA	Australia	EDQM
91	Hydroxyzine Pamoate	✓					
92	Meloxicam	✓					✓
	Total	55	23	7	14	20	57


Note : Australia accept CEP issued by EDQM

Future Growth Drivers

- Consolidate API business of Sartans across the globe.
- Long term strategic tie-ups with major South American/European formulators.
- Leverage the customer base of more than 1000 customers spread across 90 countries is well laid down platform to introduce Ipca new pipeline products.
- Increased focus in emerging markets like LATAM, CIS & China
- Own API manufacturing to back formulations, especially for the Generic market.
- Exploring strategic business relationship with smaller API manufacturers for increasing product basket.

Research & Development

APIs & Formulations



R & D Spending		
Year	Rs. Crs	% to Sales
2018-19	89.35	2.50%
2019-20	101.04	2.35%
2020-21	126.67	2.49%
2021-22	141.46	2.63%
2022-23	156.49	2.71%

- Current scientist manpower of around 564
- Research focus on developing APIs with non-infringing process and development of finished dosage forms.
- Development of NDDS for domestic and international market.
- 248 patent applications filed.
- Bio-tech / fermentation research facility established .
- Undertaking contract research activities for APIs & Formulations for international clients.

Inception of Advanced Biotech Lab (Biosimilar R&D)

- Established “State of the Art” R&D in 2015
- Lashed with modern equipments and HTP devices
- Capable of In-house Development from “Clone to Commercialization”
- Single-use Manufacturing Facility (DS+DP-cGMP) to be Ready by Dec., 2023
- Scientific Staff : 70+
- Products: Mammalian based “mAbs”

➤ Molecules: Anti-cancer and Anti-inflammatory mAbs

Molecules	Stage of Development			
	Development	Pre-clinical	Clinical Trials	MAA/Launch
				UK/IN/EU
mAb1	➔ 2022-23			2024-25
mAb2	➔ 2023-24			2024-25
mAb3	➔ 2023		➔	2026-27
mAb4	➔ 2023		➔	2026-27
mAb5	➔ 2023	➔ 2024		
mAb6	➔ 2023	➔ 2024		

- 6 monoclonal antibodies (mAbs) at various stage of the development
- Target markets India, UK, EU, ROW followed by USA
- Sought EMA and MHRA-UK Scientific Advice for mAb1 & mAb2
- Three Biosimilars in the Market (India)-P2P
- Open for the Collaboration & Out-licensing of the Technology

Thank you

No part of this corporate presentation may be re-produced, quoted or circulated without prior approval of Ipca Laboratories Limited.

This presentation may include forward looking statements based on our current business expectations. Our actual results may differ from what is projected in this corporate presentation. The viewers of this presentation may use their own judgment and calculation before making any decision on any matter based on the information given herein.

The company also disclaims any obligation to revise any of the information given in this presentation.